Evidence map›Paper›PMID 40167984›Full record

ArticleInternational urology and nephrology2025

Elevated lipoprotein-associated phospholipase A2 as a biomarker for cognitive impairment in chronic kidney disease.

Sujuan Feng, Yanfeng Lin, Rong Wang, Xingxing Fang, Jiaqi Shi, Xiameng Gu, Yang Yu

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sujuan Feng *Department of Nephrology, Affiliated Hospital 2 of Nantong University, Nantong, 226000, China.
Yanfeng Lin *Hemodialysis center, Affiliated Haimen Hospital of Xinglin College, Nantong University, Nantong, 226000, China.
Rong Wang *Department of Nephrology, Affiliated Hospital 2 of Nantong University, Nantong, 226000, China.
Xingxing FangDepartment of Nephrology, Affiliated Hospital 2 of Nantong University, Nantong, 226000, China.
Jiaqi ShiDepartment of Nephrology, Affiliated Hospital of Nantong University, Nantong, 226000, China.
Xiameng GuDepartment of Nephrology, Affiliated Hospital of Nantong University, Nantong, 226000, China.
Yang YuDepartment of Nephrology, Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), No. 881 of Yonghe Road, Nantong, 226000, China. yuyangyy0609@126.com.

Funding

Jiangsu Province Administration of Traditional Chinese Medicine MS2021060Research project of Nantong Municipal Health Commission in 2022 MS2022022Research project of Nantong University 2022HY003
6 · The paper itself

Abstract

objectiveThis study aimed to examine the relationship between serum lipoprotein-associated phospholipase A2 (Lp-PLA2) levels and cognitive impairment (CI) in patients with chronic kidney disease (CKD).

methodsA total of 125 patients with CKD treated in the Department of Nephrology, The Second Affiliated Hospital of Nantong University from July 2022 to May 2023 were selected and divided into observation group (44 patients with CI) and control group (81 patients with normal cognitive function). Multivariate logistic regression analysis was performed to analyze the risk factors of CI, and Spearman rank correlation analysis was used to analyze the correlation between serum Lp-PLA2 and Montreal Cognitive Assessment Scale (MoCA) score. The truncation value of Lp-PLA2 in CKD patients with CI was analyzed by receiver operating characteristic curve (ROC).

resultsSerum Lp-PLA2 levels were significantly elevated in the observation group compared to the control group (P < 0.05). The area under the ROC curve for Lp-PLA2 was 0.849, with a cutoff value of 232 ng/mL for identifying CI in patients with CKD. Lp-PLA2 levels were independently associated with CI in patients with CKD (odds ratio [OR] = 0.988, 95% confidence interval [CI]: 0.982-0.993, P < 0.001).

conclusionElevated serum Lp-PLA2 levels serve as an independent risk factor for CI in patients with CKD.

Indexed as

1-Alkyl-2-acetylglycerophosphocholine EsteraseCognitive DysfunctionRenal Insufficiency, ChronicAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle Aged1-Alkyl-2-acetylglycerophosphocholine EsteraseBiomarkersPLA2G7 protein, humanChronic kidney diseaseCognitive impairmentCorrelation analysisLipoprotein-associated phospholipase A2MoCA score

Identifiers

PMID40167984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.